Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?

Abstract

Hypertriglyceridaemia is a risk factor for cardiovascular disease in patients suffering from Type II diabetes mellitus, and is due to enhanced synthesis and/or impaired clearance of triacylglycerol-rich lipoproteins. In the present study we investigated whether pseudocholinesterase (PChE) activity could serve as a marker for the rate of triacylglycerol synthesis in these patients. Patients were stratified according to their apolipoprotein E (apoE) phenotype, i.e. E3E2, E3E3 or E3E4. In study I, the relationship between PChE activity and serum triacylglycerols was investigated in 224 insulin-treated patients with Type II diabetes. In study II, which had a cross-over design, PChE activity was measured in 45 dyslipidaemic, insulin-treated patients with Type II diabetes that were treated with bezafibrate or pravastatin. In study I, PChE activity was correlated positively with serum triacylglycerol concentrations, but did not differ significantly between apoE phenotypes. The strongest relationship was found in the E3E4 group (r=0.50; P=0.001), the phenotype for which hypertriglyceridaemia is expected to be the result of increased triacylglycerol synthesis. In a stepwise multiple regression analysis, serum triacylglycerol concentrations were found to be the strongest predictor of PChE activity in the E3E4 group. In study II, PChE activity decreased as a result of bezafibrate treatment in all three apoE groups. The decrease in PChE activity with bezafibrate treatment paralleled the decrease in serum triacylglycerol concentrations in the apoE subgroups. Pravastatin treatment did not significantly affect PChE activity. Thus the present study suggests an association between PChE activity and the rate of triacylglycerol synthesis. Measurement of PChE activity may therefore be a useful tool in the choice of drug for treatment of hypertriglyceridaemia in patients with Type II diabetes.

Changes in Butyrylcholinesterase Activity and Serum Lipids after Oxprenolol and Glibenclamide Treatments in Non-diabetic Rats

“…The 11 data of Rustemeijer et al, who have found that BuChE activity in type II diabetes is directly related to TG synthesis, support this hypothesis [17]. The same authors also consider that the measurement of BuChE activity may therefore be a useful tool in the choice of drug for treatment of hypertriglyceridaemia in patients with diabetes.…”

“…High BuChE activities are typical for patients with hypercholesterolemia, hypertension, obesity and Type I or Type II diabetes [12][13][14][15][16][17].…”

The Correlative Study of Serum Pseudo-cholinesterase, Biological Parameters and Symptoms Among Occupational Workers

“…Venkata et al [18] found that pseudo-cholinesterase concentration decreased correspondingly and specifically with more functional liver cell damage. Other studies [19,20] found that plasma cholinesterase had relationship with triglycerides, HDL-C, and LDL-C. More recent reports [10,11,21,22] extended the association to wide range of variables with the metabolic syndrome including body mass index, apolipoprotein concentrations, insulin, liver enzymes, and blood pressure. Moreover, Nyblom et al [23] reported that the SGOT/ SGPT ratio can be used as an indicator of cirrhosis in alcoholic liver disease, hepatitis C and supported that the high ratio ([1.1) actually reflects cirrhotic changes in the liver.…”

Hepato and Nephrotoxicity in Male Albino Rats Exposed to Malathion and Spinosad in Stored Wheat Grains

“…Also, Mansour et al [24] found that there were no signs of toxicity noted when rats treated with spinosad. As for PChE activity results, Rustemeijer et al [33] found an association between PChE activity and the rate of triacylglycerol synthesis. Decreased PChE activity has been found in patients suffering liver dysfunction [1].…”